Loading stock data…
$20.45-0.42 (-2.01%)
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States.
Tyra Biosciences, Inc. in the Healthcare sector is trading at $20.45 with a market capitalization of $1.7B. Wall Street consensus targets $47.45 (11 analysts), implying a +132.1% move over the next 12 months. The stock is currently 50% below its 52-week high of $40.65, remaining 32.0% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$49.00M↓ | -$42.00M↓ | -$36.52M↓ | -$32.94M↓ | -$31.45M |
| Net Income | -$45.56M↓ | -$39.30M↓ | -$33.83M↓ | -$29.87M↓ | -$28.10M |
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design th...